Lyka Labs Ltd
Pharmaceuticals & Biotechnology | Small Cap
Lyka Labs Ltd, operating within the Healthcare Services sector, showcases a mixed financial performance. The company demonstrates strong solvency and profitability, driven by high equity, return on capital employed, and return on assets. However, liquidity remains a significant concern due to negligible current, quick, and cash ratios. Efficiency is also a challenge, with low turnover ratios indicating poor asset utilization. The company shows promise in operating profit and asset growth, but struggles with revenue and net income growth. While interest coverage is reasonable, the absence of equity dividend coverage raises concerns. Overall, Lyka Labs exhibits financial stability and profitability, but needs to address its liquidity and efficiency challenges to ensure long-term sustainability. The weighted average calculation method considers recent years more heavily, so improvements in recent performance could positively impact future assessments.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio4.00
- Financial Ratio4.00
- Profitability Ratio4.80
- Efficiency Ratio4.67
- Coverage Ratio5.60
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBearish
- 2 HoursBearish
- 4 HoursNeutral
- 1 DayBullish
- 1 WeekBullish
- 1 MonthNeutral
Lyka Labs Ltd, operating within the Healthcare Services sector, showcases a mixed financial performance. The company demonstrates strong solvency and profitability, driven by high equity, return on capital employed, and return on assets. However, liquidity remains a significant concern due to negligible current, quick, and cash ratios. Efficiency is also a challenge, with low turnover ratios indicating poor asset utilization. The company shows promise in operating profit and asset growth, but struggles with revenue and net income growth. While interest coverage is reasonable, the absence of equity dividend coverage raises concerns. Overall, Lyka Labs exhibits financial stability and profitability, but needs to address its liquidity and efficiency challenges to ensure long-term sustainability. The weighted average calculation method considers recent years more heavily, so improvements in recent performance could positively impact future assessments.
Overall Valuation Score
P/E RATIO (TTM)
-7.45
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
-23.98
P/B RATIO
2.60
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
1.88
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-263.49
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹67.38 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company's growth performance is mixed. While operating profit and asset growth show promise, revenue and net income growth are lacking. Earnings per share growth is also a concern. This suggests potential for future expansion if revenue and profitability can be improved. The weighted average calculation, which gives more weight to recent data, suggests that improvements in operating profit and asset growth could drive future assessments.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 125.58 | -52.06 | 19.35 | 24.32 | -7.25 |
| Operating Profit Growth Rate | 405 | -83.17 | -5.88 | 12.5 | -122.22 |
| Earnings Per Share (EPS) Growth | -437.22 | -131.64 | -82.56 | -398.67 | -225.45 |
| Asset Growth Rate | -2.11 | -18.28 | 3.29 | 12.1 | -0.57 |
| Net Income Growth Rate | -480 | -134.21 | -76.92 | -366.67 | -225 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present a mixed picture. While capital expenditures are well-managed, adjusted earnings per share, book value per share, and dividend per share are low. Cash earnings per share is also a concern. Improvements in profitability and shareholder returns are needed to enhance financial performance. The weighted average calculation method, which emphasizes recent data, suggests that improvements in cash earnings per share and adjusted earnings per share could positively impact future assessments.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 14.14 | -1.94 | -0.91 | 2.22 | -2.78 |
| Cash Earnings Per Share (Cash EPS) | 18.97 | 0.32 | 3.03 | 4.17 | -0.56 |
| Book Value Per Share | 4.83 | 14.84 | 20.61 | 28.89 | 25.83 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 7.5 | 6.3 | 9.2 | 12.3 | 11.1 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability is mixed, with strong return on capital employed and return on assets, but weak gross profit, operating, and net margins. This indicates efficient use of capital and assets, but challenges in generating profits from sales. Improving margins is key to enhancing overall profitability. The weighted average calculation method, which emphasizes recent data, suggests that improvements in gross profit and operating margins could positively impact future assessments.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 43.3 | 3.23 | 2.7 | 7.97 | -9.38 |
| Return on Capital Employed (ROCE) | 61 | 5 | 4 | 10 | -6 |
| Return on Equity (ROE) | 271.43 | -28.26 | -4.41 | 7.69 | -10.75 |
| Return on Assets (ROA) | 54.3 | 11.18 | 10.19 | 10.23 | -2.29 |
| Operating Margin | 52.06 | 18.28 | 14.41 | 13.04 | -3.12 |
| Net Margin | 19.59 | -13.98 | -2.7 | 5.8 | -7.81 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency in utilizing its assets is generally weak. While Days Sales in Inventory and Receivable Days are well-managed, fixed asset, inventory, receivables, and capital turnover ratios are low. This could indicate underutilization of assets or inefficiencies in operations. Improvements in asset management could enhance overall performance. The weighted average calculation method, which emphasizes recent data, suggests that the low turnover ratios in recent years have significantly impacted the overall assessment.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 2.06 | 1.37 | 1.91 | 1.62 | 1.47 |
| Inventory Turnover Ratio | 17.59 | 11.88 | 13.08 | 11.62 | 10.73 |
| Receivables Turnover Ratio | 14.31 | 4.82 | 4.71 | 3.94 | 3.28 |
| Days Sales in Inventory Ratio | 20.75 | 30.72 | 27.91 | 31.41 | 34.02 |
| Receivable Days | 25.51 | 75.73 | 77.49 | 92.64 | 111.28 |
| Capital Turnover Ratio | 2.53 | 0.83 | 0.99 | 1.12 | 1.1 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios are mixed. While the interest coverage ratio is adequate, the absence of equity dividend coverage raises concerns about shareholder returns. Improving both interest and dividend coverage would enhance financial stability and investor confidence. The weighted average calculation method, which emphasizes recent data, suggests that improvements in interest coverage could positively impact future assessments.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 3.95 | -0.08 | 0.8 | 6.5 | -3 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency position is strong, characterized by a high equity ratio and low debt ratios. This indicates a robust capital structure and a reduced risk of financial distress. This indicates a high reliance on equity financing. The weighted average calculation, which gives more weight to recent data, suggests that the strong solvency observed in recent years is sustained and impactful.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.82 | 0.59 | 0.4 | 0.16 | 0.2 |
| Debt to Equity Ratio | 4.56 | 1.44 | 0.67 | 0.19 | 0.25 |
| Equity Ratio | 0.18 | 0.41 | 0.6 | 0.84 | 0.8 |
| Debt To Asset Ratio | 0.34 | 0.44 | 0.29 | 0.12 | 0.13 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is weak, indicating potential difficulties in meeting its short-term obligations. While maintaining sufficient liquidity is essential for smooth operations, the company's current levels are not sufficient. This necessitates a strategic review of working capital management practices. The weighted average calculation emphasizes recent data, suggesting that the sustained low liquidity over the past few years significantly impacts the overall assessment. Future improvements in current assets and liabilities could improve the company's score.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 0.68 | 1.72 | 1.74 | 1.74 | 1.47 |
| Quick Ratio | 0.6 | 1.54 | 1.52 | 1.5 | 1.24 |
| Cash Ratio | 0.16 | 0.3 | 0.14 | 0.03 | 0.02 |
| Operating Cash Flow Ratio | 0.72 | 0.23 | 0.05 | 0.04 | 0.09 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 2 | SMS Lifesciences India Ltd | 6.59 | 21.20 | Undervalued | 45.00 | 70.68 | 19.00 |
| 3 | Infinium Pharmachem Ltd | 6.42 | 26.90 | Neutral | 22.00 | 6.43 | 14.00 |
| 4 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 59.71 | Neutral | 7.00 | 1.40 | 4.00 |
| 5 | Albert David Ltd | 5.63 | -272.47 | Neutral | 5.00 | -2.62 | -1.00 |
| 6 | BPL Ltd | 5.46 | -31.11 | Neutral | -4.82 | -3.00 | -8.55 |
| 7 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 8 | Quest Laboratories Ltd | 5.27 | 11.21 | Neutral | 18.00 | 9.16 | 15.00 |
| 9 | Sotac Pharmaceuticals Ltd | 5.27 | 21.26 | Neutral | 18.00 | 4.45 | 6.00 |
| 10 | Lyka Labs Ltd | 4.77 | -23.98 | Neutral | -4.00 | -9.05 | -10.00 |
| 11 | Krebs Biochemicals & Industries Ltd | 4.16 | -5.27 | Highly Undervalued | -4.00 | -12.49 | -4.00 |
| 12 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
Lyka Labs demonstrates mixed management effectiveness. Compounded sales growth shows some promise over 5 years, but recent performance has been inconsistent. Profitability has been volatile, with negative figures in several years, though recent improvements are noted. The company's ROCE is low, indicating inefficient capital use. Debt has decreased, which is a positive sign. Promoter holding has increased, suggesting greater alignment with shareholder interests, but FII holdings have declined. Overall, management faces challenges in sustaining profitability and improving capital efficiency.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 58.16% | Increasing promoter holding indicates confidence. |
| Debt Management | Borrowings Decreasing | Decreasing debt suggests improved financial prudence. | |
| CONS | ROCE | 2.54% | Low ROCE indicates inefficient capital allocation. |
| ROE | -3.04% | Negative ROE reflects poor return on equity. |
Financial Performance & Growth
Lyka Labs' financial performance presents a mixed picture. While the compounded sales growth over 5 years is 18%, the 3-year growth is -11%, indicating recent challenges. The TTM sales growth is 25%, suggesting a potential turnaround. However, the compounded profit growth is -43% over 3 years, despite a 375% TTM growth. Operating Profit Margin (OPM) has fluctuated, with recent quarterly OPM ranging from 7.27% to 15.36%. Net profit has been volatile, with significant losses in some quarters and years, although recent quarters show improvement. Overall, the company's financial performance lacks consistency and stability.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Sales Growth (%) | -1.91% | 47.12% | 18% | -11% | 25% |
| Profit Growth (%) | -31.6% | -31.6% | 18% | -43% | 375% |
Capital Efficiency & Returns
Lyka Labs exhibits poor capital efficiency and returns. The current ROCE is 2.54%, and the ROE is -3.04%, both indicating inefficient use of capital and shareholder funds. The ROCE has been fluctuating over the years, with a high of 61% in Mar 2022 but generally remaining low. The negative ROE further emphasizes the company's struggle to generate returns from its equity. These metrics suggest significant weaknesses in how the company manages its capital and generates profits.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | ROCE (%) | 6.33% | -6% | 23.67% | 5% | 4% | 10% |
Financial Health & Prudence
Lyka Labs demonstrates mixed financial health. While the company has reduced its borrowings over the years, from ₹ 164 Cr in Jun 2014 to ₹ 39 Cr in Mar 2025, indicating improved debt management. The company has not been paying dividends, suggesting a focus on reinvesting profits or a lack of sufficient profitability. Overall, the financial health shows some positive trends in debt reduction, but persistent profitability issues are a concern.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | Borrowings (Cr) | 140.67 | 107 | 144.67 | 75 | 59 | 39 |
Shareholding & Ownership Structure
Lyka Labs shows a positive trend in its shareholding structure. The promoter holding has increased significantly over the years, from 23.99% in Mar 2017 to 58.16% in Mar 2025, indicating strong confidence from the promoters. However, the FII stake has decreased from 4.74% in Mar 2017 to 0.24% in Mar 2025, which could be a concern. DII holding has fluctuated but remains relatively low. The increase in promoter holding is a positive sign, suggesting alignment with shareholder interests.
| Metric | 2017 | 2019 | 2021 | 2023 | 2025 |
|---|---|---|---|---|---|
| Promoter Holding (%) | 23.99 | 18.13 | 19.88 | 51 | 58.16 |
| FII Holding (%) | 4.74 | 3.64 | 3.5 | 0.18 | 0.24 |
Lyka Labs exhibits moderate risk. While the company has reduced its debt and increased promoter holding, its volatile financial performance and low capital efficiency pose concerns. Fluctuations in sales and profitability, coupled with a negative ROE, indicate potential operational and financial risks.
Off-balance sheet exposure quantification
There is no specific data available on off-balance sheet exposures for Lyka Labs. Without this information, it is difficult to assess the potential risks and liabilities that are not reflected on the company's balance sheet.
Contingent liability evaluation
There is no specific data available to evaluate contingent liabilities. The absence of information on potential obligations that depend on future events makes it difficult to fully assess the company's risk profile.
Segment performance volatility
There is no specific data available on segment performance volatility. Without detailed segment information, it is challenging to assess the consistency and stability of individual business units.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
- IndicatorValueSignal
- SMA 1069.15Bearish
- SMA 2069.93Bearish
- SMA 5070.37Bearish
- EMA 1068.79Bearish
- EMA 2069.46Bearish
- EMA 5069.38Bearish
- DEMA 1067.86Bearish
- DEMA 2068.69Bearish
- DEMA 5070.85Bearish
- TEMA 1067.45Bullish
- TEMA 2067.95Bearish
- TEMA 5069.75Bearish
- MACD-0.66Bearish
- ADX16.75Weak Trend
- IndicatorValueSignal
- RSI40.70Neutral
- CCI-169.69Oversold
- ROC 9-5.10Bearish
- ROC 14-3.09Bearish
- ROC 25-4.26Bearish
- Stoch K11.79Oversold
- Stoch D12.12Oversold
- IndicatorValueSignal
- BB Upper72.53Neutral
- BB Middle69.93Neutral
- BB Lower67.33Neutral
- ATR1.57Low Volatility
- IndicatorValueSignal
- MFI18.45Oversold
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1069.47Bearish
- SMA 2070.13Bearish
- SMA 5068.00Bearish
- EMA 1069.05Bearish
- EMA 2069.46Bearish
- EMA 5067.89Bearish
- DEMA 1068.15Bearish
- DEMA 2069.58Bearish
- DEMA 5070.95Bearish
- TEMA 1067.57Bullish
- TEMA 2068.25Bearish
- TEMA 5071.44Bearish
- MACD-0.09Bearish
- ADX22.29Weak Trend
- IndicatorValueSignal
- RSI43.61Neutral
- CCI-178.74Oversold
- ROC 9-4.26Bearish
- ROC 14-3.55Bearish
- ROC 25-1.89Bearish
- Stoch K8.81Oversold
- Stoch D10.70Oversold
- IndicatorValueSignal
- BB Upper72.91Neutral
- BB Middle70.13Neutral
- BB Lower67.34Neutral
- ATR2.13Low Volatility
- IndicatorValueSignal
- MFI25.44Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
- IndicatorValueSignal
- SMA 1069.81Bearish
- SMA 2069.67Bearish
- SMA 5063.93Bullish
- EMA 1069.22Bearish
- EMA 2068.36Bearish
- EMA 5065.27Bullish
- DEMA 1069.27Bearish
- DEMA 2070.67Bearish
- DEMA 5069.29Bearish
- TEMA 1068.12Bearish
- TEMA 2070.42Bearish
- TEMA 50N/AN/A
- MACD1.52Bearish
- ADX37.41Strong Trend
- IndicatorValueSignal
- RSI50.92Neutral
- CCI-72.20Neutral
- ROC 9-3.35Bearish
- ROC 14-5.76Bearish
- ROC 2517.04Bullish
- Stoch K9.25Oversold
- Stoch D19.24Oversold
- IndicatorValueSignal
- BB Upper74.55Neutral
- BB Middle69.67Neutral
- BB Lower64.80Neutral
- ATR3.06Low Volatility
- IndicatorValueSignal
- MFI19.70Oversold
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1068.96Bullish
- SMA 2064.14Bullish
- SMA 5061.47Bullish
- SMA 10062.05Bullish
- SMA 20075.26Bearish
- EMA 1068.31Bullish
- EMA 2065.76Bullish
- EMA 5063.03Bullish
- EMA 10065.30Bullish
- EMA 20075.07Bearish
- DEMA 1071.23Bearish
- DEMA 2069.43Bullish
- DEMA 5063.80Bullish
- DEMA 10057.12Bullish
- DEMA 20055.71Bullish
- TEMA 1071.67Bearish
- TEMA 2071.22Bearish
- TEMA 5068.30Bullish
- TEMA 10061.21Bullish
- TEMA 20052.15Bullish
- MACD2.92Bullish
- ADX25.44Strong Trend
- IndicatorValueSignal
- RSI62.54Neutral
- CCI80.37Neutral
- ROC 1420.17Bullish
- ROC 2512.56Bullish
- Stoch K68.36Neutral
- Stoch D69.66Neutral
- IndicatorValueSignal
- BB Upper74.83Neutral
- BB Middle64.14Neutral
- BB Lower53.45Neutral
- ATR4.19Low Volatility
- IndicatorValueSignal
- MFI75.81Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 2061.07Bullish
- SMA 5080.34Bearish
- EMA 2064.55Bullish
- EMA 5078.32Bearish
- DEMA 2057.28Bullish
- DEMA 5057.53Bullish
- TEMA 2061.03Bullish
- TEMA 5051.16Bullish
- MACD-4.62Bullish
- ADX36.34Strong Trend
- IndicatorValueSignal
- RSI46.77Neutral
- CCI-45.55Neutral
- ROC 1415.65Bullish
- ROC 25-7.77Bearish
- Stoch K72.78Neutral
- Stoch D68.18Neutral
- IndicatorValueSignal
- BB Upper73.46Neutral
- BB Middle61.07Neutral
- BB Lower48.67Neutral
- ATR7.85High Volatility
- IndicatorValueSignal
- MFI55.50Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 662.16Bearish
- SMA 1281.17Bearish
- SMA 24106.13Bearish
- EMA 664.18Bearish
- EMA 1277.56Bearish
- EMA 2493.07Bearish
- DEMA 652.47Bullish
- DEMA 1256.34Bullish
- DEMA 2475.30Bearish
- TEMA 653.61Bullish
- TEMA 1248.94Bullish
- TEMA 2456.94Bullish
- MACD-8.23Bearish
- ADX23.90Weak Trend
- IndicatorValueSignal
- RSI43.30Neutral
- CCI-192.65Oversold
- ROC 25-51.78Bearish
- ROC 50-56.94Bearish
- Stoch K9.77Oversold
- Stoch D30.15Neutral
- IndicatorValueSignal
- BB Upper167.04Neutral
- BB Middle101.03Neutral
- BB Lower35.03Neutral
- ATR19.87Low Volatility
- IndicatorValueSignal
- MFI37.55Neutral